CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD 143.22
+2.91 (2.07%)
Apr 8, 2026, 1:05 PM AEST
CSL Limited Employees
CSL Limited had 29,904 employees as of June 30, 2025. The number of employees decreased by 2,794 or -8.54% compared to the previous year.
Employees
29,904
Change (1Y)
-2,794
Growth (1Y)
-8.54%
Revenue / Employee
772.41K AUD
Profits / Employee
69.99K AUD
Market Cap
67.32B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 29,904 | -2,794 | -8.54% |
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | 25,000 | -2,000 | -7.41% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| Clarity Pharmaceuticals | 88 |
| Mesoblast | 81 |
| Starpharma Holdings | 40 |
| Opthea | 33 |
CSL Limited News
- 4 weeks ago - CSL announces expansion of Illinois plasma therapy manufacturing facility - PRNewsWire
- 2 months ago - Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited - Business Wire
- 4 months ago - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PRNewsWire
- 5 months ago - CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) - PRNewsWire
- 6 months ago - Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines - PRNewsWire
- 8 months ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 10 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 11 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire